Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Neena Mishra headshot

Invest Like Warren Buffett with These Stocks & ETF

by Neena Mishra

Moat investing, popularized by Buffett, looks for attractively priced companies with sustainable competitive advantages.

Paratek (PRTK) Gets FDA Approval for Nuzyra and Seysara

by Zacks Equity Research

Paratek (PRTK) gets FDA approval for Nuzyra for the treatment of serious community-acquired bacterial infections and Seysara for the treatment of acne.

    5 Best Biotech Stocks to Buy In October

    by Zacks Equity Research

    Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October

      Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs

      by Zacks Equity Research

      FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K

        Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA

        by Zacks Equity Research

        FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.

          Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap

          by Zacks Equity Research

          Aldeyra Therapeutics' (ALDX) dry eye candidate, reproxalap, achieves early onset of improvement in patients and a broad range of activity.

            3 Drug/Biotech Stocks in Focus on World Alzheimer's Day

            by Zacks Equity Research

            We take a look at companies with prospective Alzheimer's Disease candidates in pipeline on World Alzheimer's Day.

              AbbVie Faces California Insurance Department Suit for Humira

              by Zacks Equity Research

              AbbVie's (ABBV) shares fall on a lawsuit by California insurance department accusing it of giving illegal kickbacks to doctors for prescribing Humira.

                Viking Therapeutics Liver Candidate Passes Test, Shares Soar

                by Zacks Equity Research

                Viking Therapeutics (VKTX) pipeline candidate, VK2809, achieves statistically significant reduction in liver fat content and bad cholesterol levels in a phase II study, evaluated for NAFLD.

                  Allergan Frown Lines Study Passes Test on Higher Botox Dose

                  by Zacks Equity Research

                  Allergan (AGN) presents positive results from a study, evaluating a higher dose of Botox for the treatment of glabellar lines.

                    Ironwood Stock Up, Heart Candidate Gets Fast Track Status

                    by Zacks Equity Research

                    The FDA confers fast track designation on Ironwood's (IRWD) praliciguat for the treatment of heart failure with preserved ejection fraction.

                      Is Allergan (AGN) a Great Stock for Value Investors?

                      by Zacks Equity Research

                      Let's see if Allergan (AGN) stock is a good choice for value-oriented investors right now from multiple angles.

                        Foamix's Acne Candidate Succeeds in Study, Shares Rally

                        by Zacks Equity Research

                        Foamix's (FOMX) acne candidate, FMX101, meets co-primary endpoints in the third phase III study, FX2017-22.

                          Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs

                          by Zacks Equity Research

                          Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.

                            AbbVie Posts Positive Data on Elagolix for Uterine Fibroids

                            by Zacks Equity Research

                            AbbVie (ABBV) reports positive top-line results from a phase III extension trial on its investigational candidate Elagolix for treating uterine fibroids in women.

                              Ironwood's Linzess Gets Approval in Japan for New Indication

                              by Zacks Equity Research

                              Ironwood Pharmaceuticals (IRWD) along with its partner Astellas Pharma announces approval of Linzess in Japan for a new indication - chronic constipation.

                                Allergan Falls on FDA's Rejection of Uterine Fibroids Drug

                                by Zacks Equity Research

                                FDA rejects Allergan's (AGN) new drug application for Esmya for the treatment of abnormal uterine bleeding in women with uterine fibroids, citing safety issues.

                                  Amgen Stock Up This Year So Far: Will the Rally Continue?

                                  by Zacks Equity Research

                                  After a relatively strong performance so far this year, let's see how things are poised for Amgen (AMGN) in the second half of the year.

                                    What's in Store for Amgen (AMGN) in Second Half of 2018?

                                    by Zacks Equity Research

                                    After a relatively strong first half, let's see how things are poised for Amgen (AMGN) in the second half of the year.

                                      Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

                                      by Zacks Equity Research

                                      Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.

                                        Allergan's (AGN) Stock Up 4.2% Since Q2 Earnings: Here's Why

                                        by Zacks Equity Research

                                        Allergan (AGN) is having a relatively better 2018 with the stock on an upward trajectory since announcement of earnings in July. Let us have a look at the reasons for the same.

                                          The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

                                          by Zacks Equity Research

                                          The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

                                            BioDelivery (BDSI) Q2 Loss Narrows, Sales Miss, Shares Down

                                            by Zacks Equity Research

                                            BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q2. Sales marginally miss the consensus mark.

                                              Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

                                              by Zacks Equity Research

                                              Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

                                                Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down

                                                by Zacks Equity Research

                                                Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.